𝔖 Bobbio Scriptorium

✦ LIBER ✦

Safety, Efficacy and Development of Resistance under the New Protease Inhibitor Lopinavir/Ritonavir: 48-Week Results

✍ Scribed by E. Voigt; J.-C. Wasmuth; M. Vogel; S. Mauss; G. Schmutz; R. Kaiser; J.-K. Rockstroh

Book ID: 107705263
Publisher: Springer-Verlag
Year: 2004
Tongue: English
Weight: 327 KB
Volume: 32
Category: Article
ISSN: 0300-8126
DOI: 10.1007/s15010-004-3059-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Once-daily atazanavir/ritonavir versus t

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

✍ Jean-Michel Molina; Jaime Andrade-Villanueva; Juan Echevarria; Ploenchan Chetcho 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 246 KB

Dual therapy with lopinavir and ritonavi

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

✍ Cahn, Pedro; Andrade-Villanueva, Jaime; Arribas, José R; Gatell, José M; Lama, J 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 321 KB

Simplification to coformulated elvitegra

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial

✍ Arribas, Jose R; Pialoux, Gilles; Gathe, Joseph; Di Perri, Giovanni; Reynes, Jac 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 260 KB